Saturday 17 October 2026
Export PGEN’s income statement to Excel — free account
Precigen, Inc.
PGEN Healthcare Biotechnology
Precigen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.7 million, up 146.7% from fiscal 2024. In the quarter to June 2026, revenue grew 6,322.7%, EPS grew 166.7% and free cash flow grew 8.73%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.35
0.85
−11.81%
Follow PGEN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (9,907.46%) | (12,417.99%) | (1,446.02%) | (875.87%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
4 | 4 | 3 | 4 | |
| (247.40%) | (286.76%) | (285.69%) | (334.36%) | ||
ROIC |
(24.87%) | (102.06%) | (425.63%) | (538.41%) | |
Return on Tangible Assets |
(285.75%) | (408.82%) | (468.60%) | (379.08%) | |
Average Days of Receivables |
306.78 | 308.51 | 164.41 | 63.64 | |
Free Cash Flow per Share |
(0.32) | (0.33) | (0.29) | (0.25) | |
Free Cash Flow |
(115.22) | (116.96) | (89.83) | (75.62) | |
Capital Expenditures |
(1.06) | (1.63) | (1.99) | (3.00) | |
| Other line items | |||||
Cash ROIC |
(65.59%) | (68.80%) | (42.38%) | (29.55%) | |
Accounts Receivable Turnover |
2.36 | 2.28 | 3.51 | 6.90 | |
Accounts Payable Turnover |
1.73 | 2.21 | 0.62 | 0.83 | |
Inventory Turnover |
0.78 | 0.84 | 0.98 | 0.56 | |
Average Days of Payables |
242.15 | 150.43 | 907.01 | 519.93 | |
Days of Inventory on Hand |
924.26 | 855.56 | 725.08 | 253.99 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
37.67% | 115.50% | 426.82% | 730.72% | |
Selling, General and Administrative Expense of Revenue |
99.09% | 249.46% | 724.16% | 1,006.23% | |
Share Based Compensation of Revenue |
15.94% | 37.10% | 117.65% | 191.71% | |
Interest Coverage |
(4.06) | (13.86) | (28.58) | (129.96) | |
Operating CF/Net income |
0.34 | 0.30 | 0.20 | 0.17 | |
Depreciation/Fixed assets |
0.28 | 0.48 | 0.38 | 0.73 | |
Capex/Depreciation |
(0.29) | (0.25) | (0.38) | (0.28) | |
Revenue per Share |
0.24 | 0.09 | 0.03 | 0.02 | |
Operating CF per Share |
(0.32) | (0.33) | (0.28) | (0.24) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
0.01 | 0.05 | 0.21 | 0.48 |
Columns are period end dates